Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 18 |
| List of Tables | 17 | 2 |
| List of Figures | 19 | 1 |
| Introduction | 20 | 1 |
| Global Markets Direct Report Coverage | 20 | 1 |
| Congestive Heart Failure (Heart Failure) Overview | 21 | 1 |
| Therapeutics Development | 22 | 2 |
| Pipeline Products for Congestive Heart Failure (Heart Failure) Overview | 22 | 1 |
| Pipeline Products for Congestive Heart Failure (Heart Failure) Comparative Analysis | 23 | 1 |
| Congestive Heart Failure (Heart Failure) Therapeutics under Development by Companies | 24 | 6 |
| Congestive Heart Failure (Heart Failure) Therapeutics under Investigation by Universities/Institutes | 30 | 2 |
| Congestive Heart Failure (Heart Failure) Pipeline Products Glance | 32 | 4 |
| Late Stage Products | 32 | 1 |
| Clinical Stage Products | 33 | 1 |
| Early Stage Products | 34 | 1 |
| Unknown Stage Products | 35 | 1 |
| Congestive Heart Failure (Heart Failure) Products under Development by Companies | 36 | 7 |
| Congestive Heart Failure (Heart Failure) Products under Investigation by Universities/Institutes | 43 | 2 |
| Congestive Heart Failure (Heart Failure) Companies Involved in Therapeutics Development | 45 | 60 |
| Amgen Inc. | 45 | 1 |
| AnGes MG, Inc. | 46 | 1 |
| Araim Pharmaceuticals, Inc. | 47 | 1 |
| ARCA biopharma, Inc. | 48 | 1 |
| Ascelegen Therapeutics, Inc. | 49 | 1 |
| Asterias Biotherapeutics, Inc. | 50 | 1 |
| Athersys, Inc. | 51 | 1 |
| Bayer AG | 52 | 1 |
| BEAT BioTherapeutics Corp. | 53 | 1 |
| BioCardia, Inc. | 54 | 1 |
| Bristol-Myers Squibb Company | 55 | 1 |
| Capricor Therapeutics, Inc. | 56 | 1 |
| Cell Therapy Limited | 57 | 1 |
| Celyad SA | 58 | 1 |
| Eli Lilly and Company | 59 | 1 |
| FibroGen, Inc. | 60 | 1 |
| GlaxoSmithKline Plc | 61 | 1 |
| Glucox Biotech AB | 62 | 1 |
| Heart Metabolics Limited | 63 | 1 |
| Hemostemix Ltd | 64 | 1 |
| Innopharmax Inc. | 65 | 1 |
| Jiangsu Hengrui Medicine Co., Ltd. | 66 | 1 |
| Juventas Therapeutics, Inc. | 67 | 1 |
| La Jolla Pharmaceutical Company | 68 | 1 |
| Laboratoires Pierre Fabre SA | 69 | 1 |
| Lead Discovery Center GmbH | 70 | 1 |
| Lee's Pharmaceutical Holdings Limited | 71 | 1 |
| Les Laboratoires Servier SAS | 72 | 1 |
| Lonestar Heart, Inc. | 73 | 1 |
| Mast Therapeutics, Inc. | 74 | 1 |
| Merck &Co., Inc. | 75 | 1 |
| Mesoblast Limited | 76 | 1 |
| miRagen Therapeutics, Inc. | 77 | 1 |
| MorphoSys AG | 78 | 1 |
| NanoCor Therapeutics, Inc. | 79 | 1 |
| Neurocrine Biosciences, Inc. | 80 | 1 |
| Novartis AG | 81 | 1 |
| Nuo Therapeutics, Inc. | 82 | 1 |
| Ono Pharmaceutical Co., Ltd. | 83 | 1 |
| Palatin Technologies, Inc. | 84 | 1 |
| Pfizer Inc. | 85 | 1 |
| PharmaIN Corporation | 86 | 1 |
| PhaseBio Pharmaceuticals, Inc. | 87 | 1 |
| Pluristem Therapeutics Inc. | 88 | 1 |
| Quantum Genomics SA | 89 | 1 |
| Recardio GmbH | 90 | 1 |
| RedHill Biopharma Ltd. | 91 | 1 |
| Renova Therapeutics Inc | 92 | 1 |
| scPharmaceuticals Inc | 93 | 1 |
| Stealth BioTherapeutics Inc. | 94 | 1 |
| Stemedica Cell Technologies, Inc. | 95 | 1 |
| Target Heart Biotec Srl | 96 | 1 |
| Theravance Biopharma, Inc. | 97 | 1 |
| TiGenix NV | 98 | 1 |
| Torrent Pharmaceuticals Limited | 99 | 1 |
| Trevena, Inc. | 100 | 1 |
| U.S. Stem Cell, Inc. | 101 | 1 |
| Vichem Chemie Research Ltd. | 102 | 1 |
| Vicore Pharma AB | 103 | 1 |
| Zensun (Shanghai) Sci &Tech Co., Ltd. | 104 | 1 |
| Congestive Heart Failure (Heart Failure) Therapeutics Assessment | 105 | 18 |
| Assessment by Monotherapy Products | 105 | 1 |
| Assessment by Combination Products | 106 | 1 |
| Assessment by Target | 107 | 6 |
| Assessment by Mechanism of Action | 113 | 6 |
| Assessment by Route of Administration | 119 | 2 |
| Assessment by Molecule Type | 121 | 2 |
| Drug Profiles | 123 | 246 |
| (sacubitril + valsartan) Drug Profile | 123 | 5 |
| AAVS-100A1 Drug Profile | 128 | 2 |
| ACP-01 Drug Profile | 130 | 3 |
| AdipoCell Drug Profile | 133 | 3 |
| aladorian sodium Drug Profile | 136 | 2 |
| ALD-201 Drug Profile | 138 | 2 |
| AMG-986 Drug Profile | 140 | 1 |
| AntimiR-199a Drug Profile | 141 | 1 |
| ARX-720 Drug Profile | 142 | 1 |
| BAY-868050 Drug Profile | 143 | 1 |
| BBR-12 Drug Profile | 144 | 1 |
| beperminogene perplasmid Drug Profile | 145 | 5 |
| BMS-986231 Drug Profile | 150 | 1 |
| bucindolol hydrochloride Drug Profile | 151 | 7 |
| C-21 Drug Profile | 158 | 2 |
| C3BSCQR-1 Drug Profile | 160 | 5 |
| CAP-1002 Drug Profile | 165 | 5 |
| Carfostin Drug Profile | 170 | 1 |
| carvedilol CR Drug Profile | 171 | 2 |
| carvedilol phosphate CR Drug Profile | 173 | 1 |
| cenderitide Drug Profile | 174 | 3 |
| cibinetide Drug Profile | 177 | 3 |
| CLR-325 Drug Profile | 180 | 1 |
| CM-1 Drug Profile | 181 | 2 |
| CTX-101 Drug Profile | 183 | 2 |
| Drug to Inhibit Calpain for Heart Failure Drug Profile | 185 | 1 |
| Drug to Inhibit Phosphoinositide 3-Kinase Gamma for Heart Failure Drug Profile | 186 | 1 |
| Drugs to Inhibit miR-425 for Hypertension and Heart Failure Drug Profile | 187 | 1 |
| ECR-A1 Drug Profile | 188 | 1 |
| elamipretide Drug Profile | 189 | 7 |
| enalapril maleate Drug Profile | 196 | 1 |
| F-373280 Drug Profile | 197 | 1 |
| FG-6874 Drug Profile | 198 | 1 |
| FG-8205 Drug Profile | 199 | 1 |
| furosemide Drug Profile | 200 | 2 |
| GDF-11 Drug Profile | 202 | 1 |
| Gene Therapy to Activate Adenylate Cyclase Type 6 for Heart Failure Drug Profile | 203 | 1 |
| Gene Therapy to Activate GLP-1 for Congestive Heart Failure Drug Profile | 204 | 1 |
| Gene Therapy to Activate UCn 2 for Congestive Heart Failure Drug Profile | 205 | 1 |
| Gene Therapy to Inhibit GRK2 for Heart Failure Drug Profile | 206 | 1 |
| Gene Therapy to Inhibit Mef2 for Heart Failure Drug Profile | 207 | 1 |
| Gene Therapy to Target mAKAPbeta for Heart Failure Drug Profile | 208 | 1 |
| GSK-2798745 Drug Profile | 209 | 1 |
| istaroxime Drug Profile | 210 | 2 |
| ITD-1 Drug Profile | 212 | 1 |
| ivabradine hydrochloride Drug Profile | 213 | 2 |
| ivabradine hydrochloride SR Drug Profile | 215 | 1 |
| JVS-100 Drug Profile | 216 | 5 |
| KBP-5074 Drug Profile | 221 | 1 |
| L-2286 Drug Profile | 222 | 1 |
| MGN-9103 Drug Profile | 223 | 2 |
| milrinone ER Drug Profile | 225 | 1 |
| Monoclonal Antibody to Inhibit Periostin1 for Congestive Heart Failure Drug Profile | 226 | 1 |
| MP-3167 Drug Profile | 227 | 1 |
| MPC-150IM Drug Profile | 228 | 5 |
| MRS-2339 Drug Profile | 233 | 1 |
| MyoCell Drug Profile | 234 | 2 |
| MyoCell SDF-1 Drug Profile | 236 | 1 |
| NBI-69734 Drug Profile | 237 | 1 |
| neladenoson bialanate Drug Profile | 238 | 1 |
| Neucardin Drug Profile | 239 | 3 |
| NM-922 Drug Profile | 242 | 1 |
| NPA-7 Drug Profile | 243 | 1 |
| Oligonucleotides for Heart Failure Drug Profile | 244 | 1 |
| omecamtiv mecarbil MR Drug Profile | 245 | 7 |
| ONO-4232 Drug Profile | 252 | 1 |
| PB-1046 Drug Profile | 253 | 2 |
| Peptide to Agonize Apelin Receptor for Diabetes and Heart Failure Drug Profile | 255 | 1 |
| Peptides to Inhibit MyBP-C/Myosin Interaction for Heart Failure Drug Profile | 256 | 1 |
| perhexiline maleate Drug Profile | 257 | 2 |
| PF-05285401 Drug Profile | 259 | 11 |
| PHIN-1138 Drug Profile | 270 | 1 |
| PL-3994 Drug Profile | 271 | 2 |
| PLX-PAD Drug Profile | 273 | 9 |
| poloxamer Drug Profile | 282 | 2 |
| pyroglutaminated serpinin Drug Profile | 284 | 1 |
| QGC-101 Drug Profile | 285 | 1 |
| REC-02 Drug Profile | 286 | 1 |
| Recombinant Protein for Congestive Heart Failure Drug Profile | 287 | 1 |
| rivaroxaban Drug Profile | 288 | 14 |
| RT-100 Drug Profile | 302 | 1 |
| RT-110 Drug Profile | 303 | 1 |
| RT-300 Drug Profile | 304 | 1 |
| RT-400 Drug Profile | 305 | 1 |
| ruboxistaurin Drug Profile | 306 | 2 |
| S-38844 Drug Profile | 308 | 1 |
| serelaxin Drug Profile | 309 | 4 |
| serpinin Drug Profile | 313 | 1 |
| SG-1002 Drug Profile | 314 | 1 |
| sildenafil citrate Drug Profile | 315 | 2 |
| Small Molecule for Target RhoGEF12 for Cardiovascular Disease Drug Profile | 317 | 1 |
| Small Molecule to Inhibit BMP for Cardiovascular, CNS, Oncology and Musculoskeletal Disorders Drug Profile | 318 | 1 |
| Small Molecule to Inhibit NOX-4 for Heart Failure Drug Profile | 319 | 1 |
| Small Molecule to Inhibit ROMK for Hypertension and Heart Failure Drug Profile | 320 | 1 |
| Small Molecules for Chronic Heart Failure Drug Profile | 321 | 1 |
| Small Molecules for Diabetes and Congestive Heart Failure Drug Profile | 322 | 1 |
| Small Molecules for Diastolic Heart Failure Drug Profile | 323 | 1 |
| Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis Drug Profile | 324 | 1 |
| Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure Drug Profile | 325 | 1 |
| Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases Drug Profile | 326 | 1 |
| Small Molecules to Inhibit G betagamma for Heart Failure, Hypertension, Inflammation and Pain Drug Profile | 327 | 1 |
| Small Molecules to Inhibit GRK2 for Heart Failure Drug Profile | 328 | 1 |
| Small Molecules to Inhibit PDE4 for Heart Failure Drug Profile | 329 | 1 |
| Small Molecules to Inhibit PDE5 for Cardiovascular Disease Drug Profile | 330 | 1 |
| Small Molecules to Taregt Beta 2 Adrenergic Receptor and Cannabinoid Receptor for Oncology, Respiratory and Cardiovascular Disorders Drug Profile | 331 | 1 |
| sodium nitrite Drug Profile | 332 | 3 |
| SP-20202 Drug Profile | 335 | 1 |
| Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology Drug Profile | 336 | 5 |
| Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure Drug Profile | 341 | 1 |
| Stem Cell Therapy for Congestive Heart Failure and Kawasaki Disease Drug Profile | 342 | 1 |
| Stem Cell Therapy for Heart failure Drug Profile | 343 | 1 |
| Stem Cell Therapy for Heart Failure Drug Profile | 344 | 1 |
| Stem Cell Therapy for Myocardial Infarction and Heart Failure Drug Profile | 345 | 1 |
| Synthetic Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases Drug Profile | 346 | 1 |
| Synthetic Peptide to Agonise Beta 2 Adrenergic Receptor for Congestive Heart Failure Drug Profile | 347 | 1 |
| Synthetic Peptide to Agonize Guanylate Cyclase A for Cardiovascular Disorders Drug Profile | 348 | 1 |
| TD-0714 Drug Profile | 349 | 2 |
| TR-4 Drug Profile | 351 | 1 |
| TRC-4186 Drug Profile | 352 | 2 |
| TRV-120023 Drug Profile | 354 | 1 |
| ularitide Drug Profile | 355 | 2 |
| VCP-746 Drug Profile | 357 | 1 |
| vepoloxamer Drug Profile | 358 | 8 |
| vericiguat Drug Profile | 366 | 1 |
| Xcel-hCardP Drug Profile | 367 | 1 |
| XEN-105 Drug Profile | 368 | 1 |
| Congestive Heart Failure (Heart Failure) Dormant Projects | 369 | 10 |
| Congestive Heart Failure (Heart Failure) Discontinued Products | 379 | 2 |
| Congestive Heart Failure (Heart Failure) Product Development Milestones | 381 | 11 |
| Featured News &Press Releases | 381 | 1 |
| Aug 08, 2016: PhaseBio Announces Dosing of First Patients in Two-Part Phase 2a Study of PB1046 in Cardiopulmonary Disorders | 381 | 1 |
| Aug 03, 2016: Mast Therapeutics Announces Issuance Of Composition Of Matter Patent Covering Vepoloxamer | 381 | 1 |
| Aug 01, 2016: Mast Therapeutics Announces Initiation Of Phase 2 Study Of AIR001 Conducted By The Heart Failure Clinical Research Network | 382 | 1 |
| Jul 01, 2016: Mesoblast Provides Update On Heart Failure Trial And Funding Of Clinical Operations | 382 | 1 |
| Jun 28, 2016: Celyad Announces Results for the CHART-1 Phase III Clinical Trial Evaluating C-Cure(R) Cell Therapy | 383 | 1 |
| Jun 27, 2016: Stealth BioTherapeutics Initiates Two Phase 2 Trials Evaluating Elamipretide for the Treatment of Heart Failure | 384 | 1 |
| Jun 22, 2016: Timely use of Novartis Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology | 385 | 1 |
| Jun 16, 2016: Capricor Therapeutics Reports Positive 12-Month Data from the DYNAMIC Clinical Trial | 385 | 2 |
| Jun 14, 2016: Mesoblast Provides Update On Global Heart Failure Program | 387 | 1 |
| Jun 09, 2016: New Review of PARADIGM-HF Results: LCZ696, an Angiotensin-neprilysin Inhibitor, Versus Enalapril in Heart Failure | 388 | 1 |
| Jun 08, 2016: Mast Therapeutics Receives Notice Of Allowance Of Composition Of Matter Patent Application Covering Vepoloxamer | 388 | 1 |
| Jun 01, 2016: Renova Therapeutics Expands Clinical Development Team With Latest Hire | 388 | 1 |
| May 23, 2016: Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at Heart Failure 2016 Congress | 389 | 1 |
| May 23, 2016: Results of Vepoloxamer Nonclinical Studies in Advanced Heart Failure Presented at European Society of Cardiology 3rd World Congress on Acute Heart Failure | 390 | 1 |
| May 21, 2016: Novartis' Entresto given strong Class I recommendation in both US and EU heart failure guidelines, less than a year after regulatory approvals | 391 | 1 |
| Appendix | 392 | 2 |
| Methodology | 392 | 1 |
| Coverage | 392 | 1 |
| Secondary Research | 392 | 1 |
| Primary Research | 392 | 1 |
| Expert Panel Validation | 392 | 1 |
| Contact Us | 392 | 1 |
| Disclaimer | 393 | 1 |
